Bristol Myers Squibb Co $51.51

up +0.39


19/9/2014 04:00 PM  |  NYSE : BMY  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get BMY Trend Analysis - it has underperformed the S&P 500 by 8%

Partner Headlines

  1. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD
  2. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin ...

    Benzinga
  3. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD
  4. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  5. Booming Biotech Market Benefits REIT BioMed Realty

    IBD
  6. Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model

    GuruFocus
  7. Bristol-Myers Drug Gets OK

    IBD
  8. Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend

    Benzinga
  9. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold

    Benzinga
  10. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD
  11. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga
  12. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD
  13. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  14. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  15. Drugmaker AstraZeneca Returns To Growth

    IBD
  16. The Stocks Already in Correction Mode

    FoxBusiness
  17. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  18. Bristol-Myers surprises Street

    IBD
  19. Thursday Morning Earnings Reports

    Benzinga
  20. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  21. Earnings Scheduled For July 24, 2014

    Benzinga
  22. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  23. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions ...

    Benzinga
  24. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  25. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  26. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  27. Bristol seeks cancer drug nod

    IBD
  28. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  29. Japan approves BMY regimen

    IBD
  30. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  31. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  32. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  33. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  34. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  35. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target By 41%

    Benzinga
  36. Benzinga's Top Downgrades

    Benzinga
  37. Ex-Dividends For July 1, 2014

    Benzinga
  38. Pfizer and others get EU nods

    IBD
  39. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  40. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  41. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  42. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment ...

    Benzinga
  43. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  44. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  45. BRISTOL-MYERS SQUIBB

    IBD
  46. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped ...

    Benzinga
  47. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  48. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  49. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  50. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
Trading Center